BIOMARIN PHARMACEUTICAL INCBMRNEarnings & Financial Report
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
BMRN Q4 2025 Key Financial Metrics
売上高
$874.6M
粗利益
$598.9M
営業利益
$-44.6M
純利益
$-46.6M
粗利益率
68.5%
営業利益率
-5.1%
純利益率
-5.3%
前年比成長
17.0%
EPS
$-0.22
資金フロー
BIOMARIN PHARMACEUTICAL INC Q4 2025 Financial Summary
BIOMARIN PHARMACEUTICAL INC reported revenue of $874.6M (up 17.0% YoY) for Q4 2025, with a net profit of $-46.6M (down 137.3% YoY) (-5.3% margin). Cost of goods sold was $275.7M, operating expenses totaled $643.5M.
Key Financial Metrics
| Total Revenue | $874.6M |
|---|---|
| Net Profit | $-46.6M |
| Gross Margin | 68.5% |
| Operating Margin | -5.1% |
| Report Period | Q4 2025 |
Revenue Breakdown
BIOMARIN PHARMACEUTICAL INC Q4 2025 revenue of $874.6M breaks down across 9 segments, led by VOXZOGO at $273.4M (31.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| VOXZOGO | $273.4M | 31.3% |
| VIMIZIM | $205.5M | 23.5% |
| PALYNZIQ | $125.3M | 14.3% |
| NAGLAZYME | $120.2M | 13.7% |
| Other | $49.4M | 5.6% |
| ALDURAZYME | $49.4M | 5.6% |
| KUVAN | $23.3M | 2.7% |
| Royalty And Other | $15.2M | 1.7% |
| ROCTAVIAN | $12.8M | 1.5% |
BIOMARIN PHARMACEUTICAL INC Revenue by Segment — Quarterly Trend
BIOMARIN PHARMACEUTICAL INC revenue by segment across the last 4 reported quarters, showing how each business line (such as VOXZOGO and VIMIZIM) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| VOXZOGO | $273.4M | $218.4M | $221.4M | $213.8M |
| VIMIZIM | $205.5M | $182.8M | $215.4M | $188.3M |
| PALYNZIQ | $125.3M | $108.8M | $105.9M | $93.3M |
| NAGLAZYME | $120.2M | $122.0M | $128.9M | $114.3M |
| Other | $49.4M | — | — | — |
BIOMARIN PHARMACEUTICAL INC Annual Revenue by Year
BIOMARIN PHARMACEUTICAL INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B). Click any linked year to see what changed vs the prior 10-K.
BIOMARIN PHARMACEUTICAL INC Quarterly Revenue & Net Profit History
BIOMARIN PHARMACEUTICAL INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $874.6M | +17.0% | $-46.6M | -5.3% |
| Q3 2025 | $776.1M | +4.1% | $-30.7M | -4.0% |
| Q2 2025 | $825.4M | +15.9% | $240.5M | 29.1% |
| Q1 2025 | $745.1M | +14.8% | $185.7M | 24.9% |
| Q4 2024 | $747.3M | +15.6% | $124.9M | 16.7% |
| Q3 2024 | $745.7M | +28.3% | $106.1M | 14.2% |
| Q2 2024 | $712.0M | +19.6% | $107.2M | 15.1% |
| Q1 2024 | $648.8M | +8.8% | $88.7M | 13.7% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $648.8M | $712.0M | $745.7M | $747.3M | $745.1M | $825.4M | $776.1M | $874.6M |
| 前年比成長 | 8.8% | 19.6% | 28.3% | 15.6% | 14.8% | 15.9% | 4.1% | 17.0% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $6.87B | $7.07B | $6.85B | $6.99B | $7.15B | $7.46B | $7.61B | $7.59B |
| 総負債 | $1.80B | $1.78B | $1.44B | $1.33B | $1.35B | $1.43B | $1.56B | $1.51B |
| 株主資本 | $5.07B | $5.29B | $5.41B | $5.66B | $5.79B | $6.03B | $6.06B | $6.09B |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $47.0M | $118.8M | $221.5M | $185.6M | $174.4M | $185.3M | $368.7M | $99.6M |